Back to Search
Start Over
Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results.
- Source :
- Journal of Ophthalmology; 10/19/2017, p1-6, 6p
- Publication Year :
- 2017
-
Abstract
- Purpose. To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods. Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results. 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA. Three years after, there was an overall mean decrease of 7 ETDRS letters, which was statistically significant. A significant improvement in the mean CRT was found at 1, 2, and 3 years. There was a significant decrease in the mean number of injections per year (7.8 to 6.5, p<0.005) between the first and third year. Conclusion. Aflibercept can be useful in the management of refractory neovascular AMD, with a good morphological response. However, in the long-term, BCVA stabilization was not achieved. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 2090004X
- Database :
- Complementary Index
- Journal :
- Journal of Ophthalmology
- Publication Type :
- Academic Journal
- Accession number :
- 125802995
- Full Text :
- https://doi.org/10.1155/2017/6835782